Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
FDA denies Teva Copaxone generic trials petition
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Pages